474 related articles for article (PubMed ID: 31463793)
21. ERα-targeted endocrine therapy, resistance and the role of GPER.
Pepermans RA; Prossnitz ER
Steroids; 2019 Dec; 152():108493. PubMed ID: 31518595
[TBL] [Abstract][Full Text] [Related]
22. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
[TBL] [Abstract][Full Text] [Related]
23. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
[TBL] [Abstract][Full Text] [Related]
24. Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer.
Hanstein B; Djahansouzi S; Dall P; Beckmann MW; Bender HG
Eur J Endocrinol; 2004 Mar; 150(3):243-55. PubMed ID: 15012607
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, and
Choudhari RC; Kaur K; Das A; Jaitak V
Curr Comput Aided Drug Des; 2024; 20(5):640-652. PubMed ID: 37888813
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
[TBL] [Abstract][Full Text] [Related]
27. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
28. Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment.
Xia X; He J; Liu B; Shao Z; Xu Q; Hu T; Yu C; Liu X; Liao Y; Liu N; Huang H
Int J Biol Sci; 2020; 16(12):2192-2204. PubMed ID: 32549765
[TBL] [Abstract][Full Text] [Related]
29. Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve η1-N, η2-N,O, η1-O, and η6 bonding modes, via a novel N-π rearrangement; relative binding affinities and computer docking studies of cis and trans-η6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERα and ERβ receptors, and growth inhibition to breast cancer cells.
Top S; Efremenko I; Rager MN; Vessières A; Yaswen P; Jaouen G; Fish RH
Inorg Chem; 2011 Jan; 50(1):271-84. PubMed ID: 21121684
[TBL] [Abstract][Full Text] [Related]
30. Discovery of natural estrogen receptor modulators with structure-based virtual screening.
Cao X; Jiang J; Zhang S; Zhu L; Zou J; Diao Y; Xiao W; Shan L; Sun H; Zhang W; Huang J; Li H
Bioorg Med Chem Lett; 2013 Jun; 23(11):3329-33. PubMed ID: 23608764
[TBL] [Abstract][Full Text] [Related]
31. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
[TBL] [Abstract][Full Text] [Related]
35. Identification of Estrogen Receptor
Pang X; Fu W; Wang J; Kang D; Xu L; Zhao Y; Liu AL; Du GH
Oxid Med Cell Longev; 2018; 2018():6040149. PubMed ID: 29861831
[TBL] [Abstract][Full Text] [Related]
36. Ligand and structure based virtual screening of chemical databases to explore potent small molecule inhibitors against breast invasive carcinoma using recent computational technologies.
Agarwal S; Dixit A; Kashaw SK
J Mol Graph Model; 2020 Jul; 98():107591. PubMed ID: 32234678
[TBL] [Abstract][Full Text] [Related]
37. Elucidating Binding Sites and Affinities of ERα Agonists and Antagonists to Human Alpha-Fetoprotein by In Silico Modeling and Point Mutagenesis.
Moldogazieva NT; Ostroverkhova DS; Kuzmich NN; Kadochnikov VV; Terentiev AA; Porozov YB
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019136
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
Lykkesfeldt AE
Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
[TBL] [Abstract][Full Text] [Related]
39. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Motomura K; Ishitobi M; Komoike Y; Koyama H; Nagase H; Inaji H; Noguchi S
Oncology; 2010; 79(1-2):55-61. PubMed ID: 21071990
[TBL] [Abstract][Full Text] [Related]
40. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
